In vitro activities of amphotericin-B in combination with rifampin against Aspergillus species

Pakistan Journal of Medical Sciences

Volumn 23, Issue 3, 2007, Pages 323-325

  Zarrin, Majid ^a   Najafi, Mohamed Reza ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amphotreicin B; Aspergillus; Rifampin; Synergism

Indexed keywords

AMPHOTERICIN B; RIFAMPICIN;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; CONTROLLED STUDY; FUNGUS ISOLATION; IN VITRO STUDY; NONHUMAN;

EID: 34347359730     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Singh N. Trends in the epidemiology of opportunistic fungal infections: redisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692-6.
2. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in an update. Eur J Clin Microbiol Infect Dis 2002;21:161-7
3. Georgopapadakou NH, Walsh TJ. Human mycoses: drugs and targets for emerging pathogens. Science 1994;264:371-3.
4. Beggs WH, Sarosi GA, Walker MI. Synergistic action of amphotericin B and rifampin against Candida species. J Infect Dis 1976;133:206-9.
5. Fujita NK, Edwards JE, Jr. Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans. Antimicrob Agents Chemother 1981;19:196-8.
6. Kobayashi GS, Medoff G, Schlessinger D, Kwan CN, Musser WE. Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science. 1972;177:709-10.
7. Rifkind D, Crowder ED, Hyland RN. In Vitro inhibition of Coccidioides immitis strains with amphotericin B plus rifampin. Antimicrob Agents Chemother. 1974;6:783-4.
8. Christension GC, Shalit I, Welch DF, Guruswamy A, Marks MI. Synergistic action of amphotericin B and rifampin against Rhizopus species. Antimicrob Agents Chemother. 1987;31:1775-8.
9. Polak A. The past, present and future of antimycotic combination therapy. Mycoses. 1999;42:355-70.
10. Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992;15:21-4.
11. Lauer BA, Reuer LB, Schroter GPJ. Susceptibility of Aspergillus to 5-fluorocytosine and amphotericin B alone and in combination. J Antimicrob Chemother. 1979;4:375-80.
12. Odds FC. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother. 1982;22:763-70.
13. Arroyo J, Medoff G, Kobayashi GS. Therapy of murine apergillosis with amphotericin B in combinmation with rifampin and amphotericin or 5-flurocystine. Antimicrob Agents Chemother. 1977;11:21-5.
14. Dannaoui E, Afeltra J, Meis JFGM, Verweij PE, Network TN. In vitro Susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother. 2002;46:2708-11.
15. Kitahara M, Seth VK, Medoff G, Kobayashi GS. Activity of amphotericin B, 5 flurocystine, and rifampicin against six clinical isolates of Aspergillus. Antimicrob Agents Chemother. 1976;9:915-9.
16. Barchiesi F, Schimizzi AM, Caselli F, Novelli A, Fallani S, Giannini D, et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:2435-41.
17. Barchiesi F, Di Francesco LF, Compagnucci P, Arzeni D, Giacometti A, Scalise G. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J Antimicrob Chemother 1998;41:59-65.
18. Louie A, Banerjee P, Drusano GL, Shayegani M, Miller MH. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemothe 1999;43:2841-7.